Yeast display of engineered antibody domains

Methods in Molecular Biology

Volumn 899, Issue , 2012, Pages 73-84

  Zhao, Qi ^a   Zhu, Zhongyu ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody domain; FACS; MACS; Yeast display

Indexed keywords

ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; FLOW CYTOMETRY; GENE LIBRARY; GENE VECTOR; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MUTAGENESIS; PEPTIDE LIBRARY; PROTEIN ENGINEERING; YEAST;

ANTIBODIES; ANTIBODY AFFINITY; FLOW CYTOMETRY; GENE LIBRARY; GENETIC VECTORS; HUMANS; MUTAGENESIS; PEPTIDE LIBRARY; PROTEIN ENGINEERING; YEASTS;

EID: 84864142367     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-921-1_5     Document Type: Article

References (15)

1. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1:755-768
2. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD (2007) Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 25:107-116
3. Walker LM, Bowley DR, Burton DR (2009) Efficient recovery of high-Af fi nity antibodies from a single-chain Fab yeast display library. J Mol Biol 389:365-375
4. Wang Z, Kim GB, Woo JH, Liu YY, Mathias A, Stavrou S, Neville DM Jr (2007) Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display af fi nity maturation of the scFv. Bioconjug Chem 18:947-955
5. Zhao Q, Feng Y, Zhu Z, Dimitrov DS (2011) Human monoclonal antibody fragments binding to insulin-like growth factors 1 and 2 with picomolar af fi nity. Mol Cancer Ther 10:1677-1685
6. Hackel BJ, Kapila A, Wittrup KD (2008) Picomolar af fi nity fi bronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuf fl ing. J Mol Biol 381:1238-1252
7. Lipovsek D (2011) Adnectins: Engineered target- binding protein therapeutics. Protein Eng Des Sel 24:3-9
8. Richman SA, Healan SJ, Weber KS, Donermeyer DL, Dossett ML, Greenberg PD, Allen PM, Kranz DM (2006) Development of a novel strategy for engineering high-Af fi nity proteins by yeast display. Protein Eng Des Sel 19:255-264
9. Dam J, Guan R, Natarajan K, Dimasi N, Chlewicki LK, Kranz DM, Schuck P, Margulies DH, Mariuzza RA (2003) Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat Immunol 4:1213-1222
10. Esteban O, Zhao H (2004) Directed evolution of soluble single-chain human class II MHC molecules. J Mol Biol 340:81-95
11. Benatuil L, Perez JM, Belk J, Hsieh CM (2010) An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel 23:155-159
12. Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). MAbs 1:26-28
13. Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: Identi fi cation of HIV-1 inhibitors. Biochem Biophys Res Commun 387:387-392
14. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284:14203-14210
15. Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS (2011) Shortened engineered human antibody CH2 domains: Increased stability and binding to the human neonatal receptor. J Biol Chem 286:27288-27293